ALT Earnings Prediction
The chart below shows how ALT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALT sees a +0.34% change in stock price 10 days leading up to the earnings, and a -3.89% change 10 days following the report. On the earnings day itself, the stock moves by +7.07%. This data can give you a slight idea of what to expect for the next quarter's release.
ALT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
5.00K
-98.62%
0.00%
Gross Margin
--
--
--
Operating Margin
-495340.00%
7855.33%
-7.40%
Net Margin
-456900.00%
7901.44%
-7.28%
EPS
-0.32
-17.95%
-8.57%
No Data Available
ALT Earnings Analysis
Altimmune, Inc. Common Stock Corporation (ALT.O) Earnings Conference Call
Positive
Cash Position Decline: Altimmune ended the third quarter of 2024 with approximately $139.4 million of cash, cash equivalents, and short-term investments, compared to $198 million at the end of 2023.
R&D Expense Increase: Research and development expenses were $19.8 million in the third quarter of 2024, compared to $18.4 million in the same period in 2023, indicating increased investment in R&D.
R&D Expenses Breakdown: Our R&D expenses for the third quarter of 2024 included approximately $12.4 million in direct costs related to development activities for pemvidutide and $0.8 million in direct costs related to additional research and discovery projects.
Administrative Expenses Increase: General and administrative expenses were $5 million in the third quarter of 2024 versus $4.5 million in the third quarter of 2023, reflecting a strategic increase in administrative support.
IND Filing Plans: We expect to file our first IND by the end of this year, with plans to initiate activities to launch that trial in the very near future.
Negative
Cash Position Decline: Altimmune ended the third quarter of 2024 with approximately $139.4 million of cash, cash equivalents, and short-term investments, compared to $198 million at the end of 2023.
Quarterly Net Loss Comparison: Net loss for the three months ended September 30, 2024 was $22.8 million, or a $0.32 net loss per share, compared to a net loss of $20.7 million or a $0.39 cent net loss per share for the third quarter of 2023.
R&D Expense Increase: Research and development expenses were $19.8 million in the third quarter of 2024, compared to $18.4 million in the same period in 2023.
Administrative Expense Increase: General and administrative expenses were $5 million in the third quarter of 2024 versus $4.5 million in the third quarter of 2023, indicating an increase in costs.
R&D Expenses Overview: R&D expenses for the third quarter of 2024 included approximately $12.4 million in direct costs related to development activities for pemvidutide.
ALT FAQs
How does ALT typically perform around its earnings report dates?
Is Altimmune, Inc. (ALT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ALT Earning Call Sentiment
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ALT.O
11.11%Positive
The earnings call reflects several concerns: increased net loss, ongoing financial challenges despite cash runway, and competitive pressures in a fast-moving market. While there is strategic development in the pipeline, uncertainties in regulatory approval and competitive landscape pose risks. Additionally, the lack of detailed guidance on new indications and study timelines adds to investor uncertainty. The Q&A session did not alleviate these concerns, as management provided limited specifics. Overall, these factors suggest a negative sentiment, likely leading to a stock price decline in the short term.
